logo
  

Biogen's Xirius Phase2/3 Study In XLRO Patients Fails To Meet Primary Endpoints

Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP.

The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints, such as a measure of visual acuity under low light conditions.

XLRP is a rare, inherited retinal disease that is associated with progressive vision loss. Cotoretigene toliparvovec or BIIB112 is an investigational AAV8 vector-based gene therapy administered by subretinal injection.

The company also announced a global collaboration and licensing agreement with ViGeneron GmbH to develop and commercialize gene therapy products based on adeno-associated virus vectors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer and Moderna have raised the prices of their respective Covid vaccines for European Union, the Financial Times reported. Pharmaceutical giants renegotiated their covid vaccine supply contract with the EU citing global inflation, supply chain bottleneck and a high demand for the vaccines. A similar price hike is expected in other markets. Shares of HSBC Holdings Plc were gaining in London and Hong Kong trading after the Asia-focused lender reported Monday that its first-half profit more than doubled, despite weak revenues. Looking ahead, the company said while uncertainties remain, the outlook is more positive with evidence of growth in strategic areas. After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention...
Follow RTT